Moch resigns as Chimerix president, CEO

Infectious disease company Chimerix Inc. (NASDAQ:CMRX) said Kenneth Moch resigned as president and CEO to pursue other interests. M. Michelle Berrey will replace Moch as president and CEO and will continue to serve as Chimerix's CMO. The company's brincidofovir ( CMX001) is in the Phase III SUPPRESS trial for cytomegalovirus (CMV) infection in adults.

Chimerix and Moch drew public ire last month after the family of Josh Hardy launched a social media campaign to get him access to brincidofovir. The company initially denied a request for compassionate-use access for Hardy, a pediatric cancer patient with an adenovirus infection. Chimerix then worked with FDA to create an open-label trial in which Hardy could participate. The trial is enrolling 20 immunocompromised patients with adenovirus infection (see BioCentury, March 31). ...